Drug recall · February 10, 2021
Metformin Hydrochloride Extended-Release Tablets recall
Why: CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120. NDC: 29033-056-01
- Lots / codes
Lot MET200601, 07/2022
- Quantity
- 7071 bottles
- Company
- Nostrum Laboratories Inc, Kansas City, MO
- Distribution
- Nationwide
- Initiated
- January 25, 2021 · Voluntary: Firm initiated
- Classified
- February 4, 2021
- Reported
- February 10, 2021
- How notified
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Metformin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.